# Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD

> **NCT02255227** · PHASE2 · TERMINATED · sponsor: **Centre Hospitalier Universitaire de Saint Etienne** · enrollment: 104 (actual)

## Conditions studied

- Infections, Pneumococcal
- Bowel Diseases, Inflammatory

## Interventions

- **BIOLOGICAL:** Prevenar 13
- **BIOLOGICAL:** Pneumo 23

## Key facts

- **NCT ID:** NCT02255227
- **Lead sponsor:** Centre Hospitalier Universitaire de Saint Etienne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-13
- **Primary completion:** 2019-08-06
- **Final completion:** 2022-07-06
- **Target enrollment:** 104 (ACTUAL)
- **Why stopped:** low inclusion rates
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02255227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02255227, "Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02255227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*